NCT02104648View on ClinicalTrials.gov

A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval

PHASE1CompletedINTERVENTIONAL
Enrollment

203

Participants

Timeline

Start Date

April 30, 2014

Primary Completion Date

August 31, 2014

Study Completion Date

August 31, 2014

Conditions
Healthy Volunteer
Interventions
OTHER

Placebo RO4602522

Daily oral doses

DRUG

RO4602522

Daily oral doses

DRUG

RO4602522

Single, oral dose

DRUG

moxifloxacin

400 mg oral dose given on Day 1 or 11

OTHER

moxifloxacin placebo

Dose given orally on Days 1 and/or 11

Trial Locations (1)

66219

Lenexa

All Listed Sponsors
lead

Hoffmann-La Roche

INDUSTRY

NCT02104648 - A 2-Part Study to Evaluate the Safety of Supra-Therapeutic Doses of RO4602522 and to Investigate the Effect of RO4602522 on the QTc Interval | Biotech Hunter | Biotech Hunter